Emerging data suggest Retatrutide , a dual stimulator targeting both incretin and another hormone, may offer a promising development for weight loss . Early clinical investigations have indicated substantial reductions in abdominal mass , possibly outperforming current body composition medications . Nevertheless , more assessment is needed to fully